agilon health inc

Agilon Health maintains a capital structure characterized by minimal leverage, with long-term debt of $15.75 million against total equity of $126.73 million, resulting in a debt-to-equity ratio of 0.12. The company holds $173.71 million in cash and equivalents, which exceeds its long-term debt obligations, providing a buffer against short-term liquidity pressures despite a reported low liquidity risk assessment. The current ratio is not explicitly provided, but the balance sheet shows total assets of $1.27 billion against total liabilities of $1.14 billion, indicating a thin equity cushion relative to the asset base.

Profitability metrics indicate significant operational challenges, with the company reporting a net loss of $391.35 million on revenues of $5.93 billion, leading to a negative return on equity of -3.09 and a negative return on assets of -0.31. The operating income stands at -$463.24 million, reflecting a substantial operating margin deficit that drives the negative EV/EBITDA multiple of -103.38. The price-to-book ratio of 379.11 suggests the market is valuing the company based on future growth expectations or intangible assets rather than current book value, as the tangible book value is negligible relative to the market capitalization of $48.05 billion.

Revenue concentration and segment details are not explicitly broken down in the available data, but the total revenue of $5.93 billion indicates a large-scale operation within the health care providers and services industry. Without specific segment or geographic data, the revenue mix cannot be further analyzed, but the scale suggests a diversified patient or provider network typical of large health care systems.

Growth trajectory analysis is limited by the absence of historical period data in the input, preventing a year-over-year or quarter-over-quarter comparison of revenue and net income trends. The current financial snapshot shows a negative operating cash flow of -$105.76 million, which, combined with capital expenditures of $13.24 million, indicates that the company is consuming cash to fund operations and investments. This cash burn rate must be monitored against the $173.71 million cash balance to assess sustainability.

Risk assessment highlights low liquidity and low dilution risks, with no immediate filing-based flags detected for liquidity or dilution. The low dilution risk is supported by the fact that basic and diluted shares outstanding are identical at 414.73 million, suggesting no significant in-the-money options or convertible securities currently impacting share count. However, the negative profitability and cash flow pose inherent operational risks that are not fully captured by the low dilution flag.

Recent observations from investor relations data show a wide dispersion in analyst price targets, with a mean of $65.79, a median of $67.00, a high of $141.00, and a low of $6.25. The mean recommendation of 2.88 indicates a mixed sentiment among analysts, with 1 strong buy, 3 buy, and 10 hold ratings, reflecting uncertainty about the company's future performance and valuation. The current market price of $115.85 is significantly above the mean and median price targets, suggesting the stock may be overvalued relative to analyst consensus.

Agilon Health Inc (AGL.O) has recorded notable additions to its shareholder base, marking the first analysis for this ticker with no prior basis for delta computation. The most significant recent activity involves a new holder acquiring 18,321,808 shares valued at approximately $12.6 million as of December 31, 2025. This addition represents a weight of 0.00018% in the investor's portfolio and was detected on June 28, 2026. In addition to the 2025 activity, the company saw other notable holder additions in previous periods. An investor added 23,220,131 shares valued at roughly $151.9 million as of June 30, 2024, accounting for a 0.0034% portfolio weight. Another notable addition occurred as of December 31, 2024, where an investor acquired 816,635 shares valued at approximately $1.6 million, representing a 0.0004% weight. These changes highlight a shift in ownership structure, with the company currently tracking 18 top holders. Despite this activity in the shareholder registry, Agilon Health currently has zero analyst coverage and zero index memberships. The officer count is also listed as zero in the current dataset, suggesting limited public disclosure of executive leadership details in this specific snapshot. The accumulation of these notable holder additions, particularly the large 2024 position valued at over $150 million, suggests growing institutional interest or rebalancing within the company's equity base. However, the absence of analyst estimates or cross-source signals means that the market sentiment remains opaque, with the primary observable metric being the mechanical addition of these specific shareholdings.